Doello Kevin, Ortiz Raúl, Alvarez Pablo J, Melguizo Consolación, Cabeza Laura, Prados José
a Medical Oncology Service, Virgen de las Nieves Hospital , Granada , Spain.
b Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada , Granada , Spain.
Nutr Cancer. 2018 May-Jun;70(4):569-578. doi: 10.1080/01635581.2018.1464347. Epub 2018 Apr 30.
Curcumin, the main active compound of the curcuma root, shows antioxidant, anti-inflammatory, and antitumor properties which have been demonstrated in preclinical and clinical trials. Its antitumor activity is mediated by its ability to act directly on the tumor cell, activating apoptosis pathways and indirectly inhibiting the process of inflammation, angiogenesis, and metastasis in the tumor microenvironment. In addition, it has a preventive activity such as radio and/or chemosensitizer. These effects have been evident in in vitro assays but have also been corroborated in patient trials either through the isolated use of curcumin or through its association with other agents. Moreover, curcumin has demonstrated a low induction of side effects. Numerous patents have been developed in connection with the administration and use of curcumin against different types of cancer. All this justifies the interest for the development of new laboratory studies and especially of clinical trials to validate this compound as a dietary supplement in both the healthy and the oncological population. The present review aims to address the most recent in vitro investigations and the latest clinical trials and patents related to the curcumin agent to provide an up-to-date overview of the latest advances in relation to its antitumor effect.
姜黄素是姜黄根的主要活性成分，具有抗氧化、抗炎和抗肿瘤特性，这些特性已在临床前和临床试验中得到证实。其抗肿瘤活性是通过直接作用于肿瘤细胞，激活凋亡途径，并间接抑制肿瘤微环境中的炎症、血管生成和转移过程来介导的。此外，它还具有诸如放射和/或化学增敏剂等预防活性。这些作用在体外试验中很明显，但在患者试验中也得到了证实，无论是通过单独使用姜黄素还是通过其与其他药物联合使用。此外，姜黄素已证明副作用诱导率较低。关于姜黄素针对不同类型癌症的给药和使用，已经开发了许多专利。所有这些都证明了开展新的实验室研究尤其是临床试验的合理性，以验证这种化合物作为健康人群和肿瘤患者膳食补充剂的有效性。本综述旨在阐述与姜黄素制剂相关的最新体外研究、最新临床试验和专利，以提供有关其抗肿瘤作用最新进展的最新概述。
